Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting
07-Jun-2010 -
Sanofi-aventis reported new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from ...
interferon
magnetic resonance imaging
medicine
+6